Complement receptor 1 and 2 fusion proteins
US8540997B2 · kind B2 · utility
0Cited by
19References
13Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jun 16, 2011 |
| Grant date | Sep 24, 2013 |
| Priority date | — |
| Expiry date | Jun 16, 2031 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Modulation of the complement system represents a therapeutic modality for numerous pathologic conditions associated with complement activation. In a strategy to prepare complement inhibitors that are targeted to sites of complement activation and disease, compositions comprising a complement inhibitor linked to complement receptor (CR) 2 are disclosed. The disclosed are compositions can be used in methods of treating pathogenic diseases and inflammatory conditions by modulating the complement system.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.